Pharmaceutical

J&J expands dermatology portfolio with $850m Proteologix acquisition

J&J has gained access to several bispecific antibody programmes, including the Phase I-ready asset PX128 for atopic dermatitis and asthma.

May 19, 2024 - 04:00
J&J expands dermatology portfolio with $850m Proteologix acquisition
J&J has gained access to several bispecific antibody programmes, including the Phase I-ready asset PX128 for atopic dermatitis and asthma.
Read the original article

Tags:

Previous Article

Direct to consumer channels change patient-healthcare system relationship

Next Article

Sanders issues warning to Novo Nordisk amid GLP-1 drug price investigation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Neurocrine reports second late-stage trial success for congenital adrenal hyperplasia drug

STAT+: Neurocrine reports second late-stage trial succe...

Oct 6, 2023

STAT+: Biotech investors push to extend time before pills are subject to price negotiations

STAT+: Biotech investors push to extend time before pil...

Oct 18, 2023

Swiss company Lonza acquires Synaffix to boost ADC offering

Swiss company Lonza acquires Synaffix to boost ADC offe...

Jun 3, 2023